Liver Transplantation Surgery Unit, LIM 37, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
Med Hypotheses. 2010 Sep;75(3):324-7. doi: 10.1016/j.mehy.2010.03.013. Epub 2010 Apr 13.
The development of an effective vaccine for hepatitis C is of paramount importance, given the global disease burden and its public health impact. We simulated a theoretical vaccine with 98% efficacy and coverage of 95% of the susceptible population, an achievable program. The simulated period of vaccination varied from 0 to 70 years and we calculated, through a mathematical model, the reduction in the number of liver transplantations carried out each year. The program is entirely inefficient until 20 years of vaccination and its impact rises linearly with time, reaching a maximum of 40% reduction. The model assumes that approximately 50% of all the liver transplantation carried out in our population are due to HCV infection. Therefore, the maximum reduction in the number of transplantation attained after 70 years is 10% less of the theoretical optimum. This is due to the 2% of primary vaccination failure plus the 5% in the coverage failure, which leaves a small proportion of susceptible individuals who will catch the infection and evolve to liver failure. In conclusion, the advent of a hepatitis C vaccine is welcome however, decision makers should be prepared for a very long time living with this scourge.
开发有效的丙型肝炎疫苗至关重要,因为它在全球范围内造成了疾病负担并对公共卫生产生了影响。我们模拟了一种理论上具有 98%疗效且易感人群覆盖率为 95%的疫苗,这是一个可行的方案。接种疫苗的模拟时间从 0 年到 70 年不等,我们通过数学模型计算了每年进行的肝移植数量的减少。该方案在接种疫苗 20 年内完全无效,其影响随时间呈线性增加,达到 40%的最大减少。该模型假设,我们人群中进行的所有肝移植约有 50%是由于 HCV 感染。因此,在 70 年后达到的肝移植数量的最大减少量比理论最佳值少 10%。这是由于 2%的初次接种失败加上 5%的接种覆盖率失败,这使得一小部分易感人群会感染该病毒并发展为肝功能衰竭。总之,丙型肝炎疫苗的问世是受欢迎的,但决策者应该做好长期与这种疾病作斗争的准备。